Loading...
•
Sep 30, 2023
Paysign Q3 2023 Earnings Report
Paysign reported strong top and bottom-line growth, with revenue increasing 17% year-over-year and net income improving 29%.
Key Takeaways
Paysign reported a strong third quarter with a 17% increase in revenue year-over-year and a 29% improvement in net income. The company's growth was evident across all business segments, driven by higher donor rates in the plasma business and substantial revenue growth in the patient affordability segment.
Revenue increased by 17% year-over-year.
Net income improved by 29% year-over-year.
Growth was evident across all business segments.
The company maintains a strong pipeline in every area.
Forward Guidance
Paysign expects operating improvements in the fourth quarter with year-over-year revenue growth slightly better than this quarter’s revenue growth of 17% and operating expenses equivalent to our second quarter 2023 operating expenses of $6.3 million which reflect seasonal costs relative to the third quarter
Positive Outlook
- Operating improvements expected in the fourth quarter.
- Year-over-year revenue growth expected to be slightly better than the third quarter.
- Operating expenses expected to be equivalent to the second quarter 2023 operating expenses.
- Guidance in the range of $44.0 million to $46.0 million.
- Adjusted EBITDA to be in the range of $6.0 million to $7.5 million.
Challenges Ahead
- Continued inflationary pressures across the business.
- Potential downturn in the economy could reduce customer base and demand.
- Operating in a highly regulated environment.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...